Focus on the NB Redesignation Status & Timeline, Rationale for Prioritization of Specific Product Line Compliance with New Rules & Management of Remaining Tasks, all while Addressing Ongoing MDR Uncertainties in Finalizing the Updated Regulatory Strategy